Document is current

Article History

Received: 6 August 2024

Accepted: 12 February 2026

First Online: 25 February 2026

Declarations

:

: The methods were carried out following the relevant guidelines and regulations. The ERBITAG study was conducted in accordance with the Declaration of Helsinki. Approval was granted by the ethics committee of the coordinating investigator (ethics committee of the Medical Association of Westphalia-Lippe and the Medical Faculty of the Westphalia Wilhelms University Münster). All study-relevant data were documented in a pseudonymous manner. Patients provided written informed consent prior to inclusion in the study.

: Not applicable.

: SWS holds shares and stock options from Merck and received honoraria from MSD and research grant/funding from Merck. UPN received honoraria from Merck, Astellas, Dr. Falk Pharma international, Astra Zeneca, Roche AG, Amgen, and Bristol Myers Squibb. MOZ holds shares and stock options from Gilead and Bayer and received honoraria from Bristol Myers Squibb, Astra Zeneca, NCO, Novartis, and IOMEDICO. CHS received honoraria from Novartis, and Sanofi and act as a consultant for Amgen, JJ receives sponsorship for advisory boards and study participation from the following companies: BMS, Novartis, Astra Zeneca, Roche, Pfizer, Johnson and Johnson and Ipsen. KS is a fulltime employee at Merck Germany Healthcare GmbH. JR is a fulltime employee at Merck Germany Healthcare GmbH. All other authors have no conflicts of interest.